Biotechnology · Philadelphia, Pennsylvania, United States
$4.71
+1.73% (+$0.08)2026-07-09
Smart-Money SignalNeutral · 53/100— Insiders are net buyers over 90 days ($206K, 2 buys vs 0 sales)
Net Income-$7.6M
EPS$-2.36
Market Cap$15.1M
Price Performance
Historical data including institutional events
Company Profile
W
William Chou
CEO & Executive Director
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntingtonâs disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvaniaâs Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
- Founded
- 2017
- Employees
- 24
- Headquarters
- Philadelphia, Pennsylvania, United States
- Website
- www.passagebio.com
Peer ComparisonRevenue ($B)
▾Loading company sections...